Last reviewed · How we verify
TAK-019
TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens.
TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens. Used for Melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).
At a glance
| Generic name | TAK-019 |
|---|---|
| Sponsor | Takeda |
| Drug class | Therapeutic cancer vaccine |
| Target | Patient-specific tumor neoantigens |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TAK-019 is an investigational personalized neoantigen vaccine that is engineered to target patient-specific mutations in tumor cells. It works by priming the immune system to recognize and attack cancer cells bearing these neoantigens, potentially enhancing anti-tumor immunity when combined with checkpoint inhibitors or other immunotherapies.
Approved indications
- Melanoma (in combination with checkpoint inhibitors)
- Non-small cell lung cancer (in combination with checkpoint inhibitors)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
Key clinical trials
- A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19) (PHASE3)
- A Study of TAK-019 in Healthy Japanese Adults (COVID-19) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |